Botulinum Toxin Companies | Market Research Future

Top Industry Leaders in the Botulinum Toxin Market

*Disclaimer: List of key companies in no particular orderLatest Botulinum toxin Companies Update

Sep 2023: The US Food and Drug Administration (FDA) has received resubmitted petitions from Hugel Inc., a biopharmaceutical business based in South Korea, regarding the product clearance of its botulinum toxin preparations "Letybo" in 50 and 100 units for the treatment of glabellar lines. The company applied to the FDA in October of last year for approval of the product for these two medications, and in April of this year, they received a comprehensive response letter. Hugel claims that the business has returned the application after making the required improvements to certain data, paperwork, and facility equipment following FDA regulations. After an estimated six months of examination, the company hopes to confirm the product's clearance status in the first half of the following year.

Sep 2023: According to a recent announcement from AbbVie, a late-stage trial of its novel combination medication for the treatment of a kind of blood cancer could not significantly raise patient survival rates without worsening the illness. A relapsed multiple myeloma that had undergone two or more prior therapies was being studied in patients using AbbVie's Venclyxto in combination with the steroid dexamethasone. While the results were not statistically significant, the combination of AbbVie and dexamethasone improved the median progression-free survival time to 9.9 months, as opposed to 5.8 months for a mix of Bristol-Myers Squibb's (BMY.N) Pomalyst and dexamethasone. In contrast to 35% of the individuals treated with the Pomalyst-dexamethasone combination, the business said that 62% of patients treated with the combo therapy demonstrated full elimination of tumors or reduced tumor size.

List of Botulinum toxin Key companies in the market